title: [Management of metastatic androgeno-independent prostate cancer].
abstract: After first line hormonal therapy (agonist LHRH), metastasic prostate cancer becomes androgen independent in a period of 18 months on average. After this period and after having verified the castration by blood testosterone level, a few options are possible: either inhibit adrenal androgens by maximum androgen blockage (+anti androgens) or by specific adrenal androgen inhibitors. It is also possible to use estrogen or, in a few cases, to propose chemotherapy.
authors.affiliation: Service d'Urologie, Hôpital Foch, Faculté de médecine Paris-Ile-de-France-Ouest, UVSQ, France. t.lebret@hopital-foch.org
authors.forename: T
authors.initials: T
authors.lastname: Lebret
authors.forename: A
authors.initials: A
authors.lastname: Méjean
mesh_terms: D000728:Androgens; D003663:Decision Trees; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000728:Androgens